Cabozantinib Granted Breakthrough Therapy Designation for Kidney Cancer

Share this content:

the ONA take:

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma (RCC) after a prior therapy administration.

The FDA designation was based on resulting data from METEOR, a phase 3 trial that compared  cabozantinib vs everolimus in patients with advanced renal cell carcinoma. Participants all experienced disease progression after treatment with a VEGF receptor tyrosine kinase inhibitor.

Cabozantinib displayed a significant increase in progression-free survival when compared to everolimus treatment in the first 375 randomly chosen participants, with disease progression or death dropping by approximately 42 percent. RCC treatment has historically been limited to cytokine therapy before the more recent use of targeted therapies.

The Breakthrough Therapy Designation is assigned in cases where a drug demonstrates significant benefit and/or life-saving benefits when compared to traditional therapies.

The benefits of the Breakthrough Therapy Designation may include expedited review of a New Drug Application and the involvement of senior FDA managers in the review process.

Cabozantinib, marketed in capsule form under the trade name Cometriq, is currently FDA-approved for the treatment of metastatic medullary thyroid cancer. Cabozantinib inhibits the activity of tyrosine kinases active in oncogenesis, metastasis, and tumor angiogenesis processes.

Genetic assay is predictive of prognosis for patients with kidney cancer
The FDA has granted Breakthrough Therapy Designation to cabozantinib for treatment of advanced renal cell carcinoma.
Exelixis, Inc. announced the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib, Exelixis' lead compound, as a potential treatment for patients with advanced renal cell carcinoma (RCC) who have received one prior therapy.
READ FULL ARTICLE From Business Wire
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs